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Abstract
Adipocytokines are produced by visceral fat, and levels may be associated with breast cancer risk.
We investigated whether single nucleotide polymorphisms (SNPs) in adipocytokine genes
adiponectin (ADIPOQ), leptin (LEP), and the leptin receptor (LEPR) were associated with basal-
like or luminal A breast cancer subtypes. 104 candidate and tag SNPs were genotyped in 1776 of
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2022 controls and 1972 (200 basal-like, 679 luminal A) of 2311 cases from the Carolina Breast
Cancer Study (CBCS), a population-based case–control study of whites and African Americans.
Breast cancer molecular subtypes were determined by immunohistochemistry. Genotype odds
ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic
regression. Haplotype ORs and 95% CIs were estimated using Hapstat. Interactions with waist-hip
ratio were evaluated using a multiplicative interaction term. Ancestry was estimated from 144
ancestry informative markers (AIMs), and included in models to control for population
stratification. Candidate SNPs LEPR K109R (rs1137100) and LEPR Q223R (rs1137101) were
positively associated with luminal A breast cancer, whereas ADIPOQ +45 T/G (rs2241766),
ADIPOQ +276 G/T (rs1501299), and LEPR K656N (rs8129183) were not associated with either
subtype. Few patterns were observed among tag SNPs, with the exception of 3 LEPR SNPs
(rs17412175, rs9436746, and rs9436748) that were in moderate LD and inversely associated with
basal-like breast cancer. However, no SNP associations were statistically significant after
adjustment for multiple comparisons. Haplotypes in LEP and LEPR were associated with both
basal-like and luminal A subtypes. There was no evidence of interaction with waist-hip ratio. Data
suggest associations between LEPR candidate SNPs and luminal A breast cancer in the CBCS and
LEPR intron 2 tag SNPs and basal-like breast cancer. Replication in additional studies where
breast cancer subtypes have been defined is necessary to confirm these potential associations.
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Introduction
Much of the interest in the basal-like subtype of breast cancer is due to its association with
tumor characteristics associated with poor prognosis, higher prevalence in younger and
African American women, higher prevalence among BRCA1 carriers, and poorer survival
when compared with breast cancers expressing the estrogen receptor (ER) [1–9]; however,
the etiology of this tumor subtype remains largely unknown. The Carolina Breast Cancer
Study (CBCS) previously reported that basal-like breast cancer was associated with elevated
waist-hip ratio (WHR) [10]. One potential mechanism that may explain this association is
the induction of pro-tumor pathways by adipocytokines [11, 12]. Adipocytokines are
hormones produced in visceral adipose tissue, and circulating levels are correlated with
obesity [11–13]. Adipocytokines are also expressed in breast tissue, and have been shown to
affect cell proliferation, migration, and invasion [11, 12,14]. Lower circulating levels of one
particular adipocytokine, adiponectin, have been associated with breast cancer in some
studies [15–19], though others have reported no association [20]. Case–control studies of the
association between circulating levels of another adipocytokine, leptin, and breast cancer
have been inconclusive, whereas a prospective study of leptin and breast cancer risk was
null [17, 21–24].
Studies of the association between single nucleotide polymorphisms (SNPs) in the
adiponectin (ADIPOQ), leptin (LEP), and leptin receptor (LEPR) genes and breast cancer
risk have shown little consistency [21, 25–30]. For example, LEPR Q223R is the most
commonly studied SNP in these genes, and has been reported as positively, inversely, and
not associated with breast cancer [21, 25, 27–30]. It is possible that some of the variation in
reported ADIPOQ, LEP, and LEPR SNP associations is due to tumor heterogeneity, and that
stratification by tumor subtype will reveal subtype-specific associations, as has been
demonstrated by others [10, 31–34].
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Therefore, we investigated the association between SNPs in ADIPOQ, LEP, and LEPR and
basal-like breast cancer, luminal A breast cancer, and breast cancer overall (all cases
compared to controls). The relationship between adipocytokines and visceral fat led us to
also evaluate interaction between SNPs and WHR, a proxy for central obesity. This analysis
focused on basal-like breast cancer due to the specific nature of our hypothesis that basal-
like breast cancer risk may be influenced by adipocytokines. Luminal A breast cancer was
the most common breast cancer subtype in the CBCS and shows traditional associations
with breast cancer risk factors [5, 10]; it is included in this analysis as a point of reference.
Materials and methods
Study population
The CBCS is a population-based case–control study of breast cancer in North Carolina, and
has been described previously [10, 35, 36]. Eligible cases were women aged 20–74,
diagnosed with primary invasive breast cancer from 1993 to 2001, and living within the
study area. Randomized recruitment was used to oversample African American cases and
cases younger than 50-years old [37]. Eligible women diagnosed with breast carcinoma in
situ were also enrolled from 1996 to 2001. Women aged 20 to 74 years, residing within the
study area, and without a history of breast cancer were eligible controls, and were
frequency-matched to cases by race and age.
Participants provided informed consent and completed an in-home interview about social
and demographic characteristics, medical history, and potential breast cancer risk factors.
Height, weight, waist circumference, and hip circumference were measured by a trained
nurse. Participants were also asked to provide a blood sample. DNA was extracted from
blood and stored at −80°C. A total of 2311 cases and 2022 controls were enrolled. 2045
(88%) cases and 1818 (90%) controls provided a blood sample, and 2039 (88%) cases and
1818 (90%) controls had DNA available for genotyping.
Cases provided written consent for access to medical records and formalin-fixed paraffin-
embedded tumor tissue blocks. Immunohistochemistry staining and scoring procedures for
the ER, progesterone receptor (PR), human epidermal growth factor receptors 1 and 2
(EGFR and HER2), and cytokeratin (CK) 5/6 have been described in detail by others [5, 10,
38, 39]. Tumor tissue was available for 1845 of 2311 (80%) cases, and
immunohistochemistry was completed for 1424 of 2311 (62%) cases. Tumors were
classified as follows: 225 basal-like (ER−, PR−, HER2−, CK 5/6+ and/or EGFR+), 796
luminal A (ER+ and/or PR+, HER2−), 137 luminal B (ER+ and/or PR+, HER2+), 116
HER2+/ER− (ER−, PR−, HER2+), and 150 unclassified (ER−, PR−, HER2−, CK 5/6−, and
EGFR−) [5, 39, 40]. Cases with missing subtype data were more likely to be non-African
American and to have an earlier stage at diagnosis [10].
SNP selection
SNPs were selected using pairwise tagging in Tagger (r2 ≥ 0.80) [41, 42]. The majority of
CBCS participants were white or African American, so SNPs were selected from the
International HapMap Project CEU and YRI populations; ASW genotypes were unavailable
at the time of SNP selection [43]. Tag selection was performed separately in CEU and YRI
data for SNPs with a minimum minor allele frequency (MAF) of 0.10, combined into a
single list, and genotyped in all participants. Pairwise tagging for LEPR required more than
90 SNPs; tagging was repeated using aggressive tagging, which reduced the number of
SNPs by 15 [41]. The list of tag SNPs was supplemented by “candidate” SNPs—SNPs with
a reported in vitro functional effect or that had been investigated for an association with
breast cancer risk (MAF ≥ 0.05).
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158 ancestry informative markers (AIMs) were also genotyped to estimate African and
European ancestry [44]. AIMs were selected from a panel that has been used previously by
others to estimate ancestry in African Americans, and maximized Fisher’s information
content and the difference in allele frequencies between ancestral populations [45, 46].
Genotyping results and quality control
SNPs were genotyped as part of a larger set of 1536 SNPs by the UNC Mammalian
Genotyping Core using the Illumina GoldenGate assay (Illumina, Inc, San Diego, CA).
Assay intensity data and genotype cluster images for all SNPs were reviewed individually.
163 SNPs were excluded due to low signal intensity or inability to distinguish between
genotype clusters. Blind duplicates of 169 samples were genotyped to verify the
reproducibility of genotype calls. Concordance between duplicates was greater than 99.8%
for all pairs.
Exact tests of Hardy–Weinberg equilibrium (HWE) were conducted in controls stratified by
self-identified race using Plink v1.05 [47]. In order to confirm that deviations from HWE
were not due to erroneous genotype calls, genotyping cluster images were re-reviewed for
SNPs with HWE P-values less than 0.01. SNPs reviewed during this process had acceptable
signal intensity and cluster definitions, and none were excluded. Overall, 1373 of 1536
(89%) SNPs passed quality control, including 104 of 127 (82%) in ADIPOQ, LEP, and
LEPR and 144 of 158 (91%) AIMs.
Subject data were excluded because of genotype calls for less than 95% of SNPs (N = 103),
gender mismatch (N = 5), and suspected contamination (N = 1), yielding data for 1776 of
2022 (88%) controls and 1972 of 2311 (85%) cases (Table 1). Participants without genotype
data were more likely to be cases, recruited in the second half of the study, and African
American. 1220 of 2311 (53%) cases had both genotyping and tumor subtype data; missing
genotype data were not associated with tumor subtype.
Variables
Age was defined as age at breast cancer diagnosis for cases or age at study sampling for
controls, and was included in models as a continuous variable. Self-identified race was white
for 2293 participants, African American for 1400, and missing for 2. Less than 2% of
participants reported that they were of another race, and were grouped with white women as
non-African American.
Maximum likelihood methods were used to estimate individual proportions of African and
European ancestry from 144 AIMs [48]. The median proportion of African ancestry was
81% among self-reported African Americans and 6% among self-reported non-African
Americans. African ancestry was used in regression models as a proportion ranging from 0
to 0.96 (the maximum proportion African ancestry).
Body size was measured using standardized equipment [49]. WHR was the ratio of waist
circumference to hip circumference, and was categorized based on the tertile distribution in
controls. WHR associations with basal-like and luminal A breast cancer were similar for
tertiles 2 and 3 (vs. tertile 1) [10], so those two categories were combined. Body mass index
(BMI, weight in kg/height in m2), a potential confounder of WHR associations with breast
cancer [50, 51], was included in regression models as a continuous variable. WHR and/or
BMI information were missing for 50 cases and 40 controls.
Self-reported family history of breast cancer in a first degree relative was used as a binary
variable (yes/no).
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Allele frequencies were adjusted for the sampling probabilities used to sample participants
(online resource 1). R2 was calculated in Haploview v3 [52]. Both were stratified by case
status and self-identified race.
Odds ratios (ORs) and 95% confidence intervals (CIs) for genotype associations with breast
cancer overall were estimated using unconditional binary logistic regression using SAS
v9.1.3 (SAS, Cary, NC). Associations with basal-like and luminal A breast cancers were
estimated using unconditional polytomous logistic regression and statistics testing the
equality of parameter estimates for basal-like and luminal A subtypes were calculated based
on the asymptotic chi-square distribution of the Wald statistic. Confidence limit ratios
(CLRs, upper confidence limit divided by lower confidence limit) were calculated as a
measure of relative precision [53]. As mentioned above, this analysis focused on basal-like
and luminal A breast cancer; associations for other subtypes were not evaluated.
Genotype associations were modeled using the codominant model, as this does not assume a
specific model form for the genotype effects and has greater power than other incorrectly
specified model forms when the true underlying mode of inheritance is unknown [54]. If
homozygote counts were less than 5 cases, less than 5 controls, or less than 10 cases and 10
controls, rare homozygote and heterozygote categories were combined. If results using the
co-dominant model indicated that the underlying model may be recessive or dominant
additional analyses specific to that model were conducted. Estimates for associations with
basal-like breast cancer were expected to be less precise than associations for luminal A
breast cancer due to the smaller number of basal-like cases. Therefore, the results presented
were chosen based on both the strength of the OR and precision to avoid bias in reporting
results by subtype. Associations with a relatively strong OR (OR ≥ 1.5 or OR ≤ 0.67) or a P-
value < 0.05 and a precise CI (CLR ≤ 5) are reported in the results; sample size by genotype
for these SNPs is given in online resource 2.
Models were adjusted initially for age and self-identified race, and an offset term was
included in models to account for randomized recruitment sampling [37]. Confounding due
to ancestry was assessed using the change-in-estimate approach, where a log OR change of
0.10 or more in either direction was considered a meaningful difference. Adjustment for
ancestry changed log ORs by more than 0.10 for the association between a subset of SNPs
and luminal A breast cancer, and so models were also adjusted for ancestry. Residual
confounding by family history of breast cancer was assessed using the same approach.
Additional adjustment for family history of breast cancer only affected the results for two
SNPs (rs6413506 and rs4655555), and so family history was added to the final regression
models for these SNPs only.
Log-additive model ORs and P-values were also calculated for SNP associations. Monte
Carlo methods were used to approximate the joint distribution of test statistics and evaluate
the family wise error rate to control for multiple comparisons [55]. Estimation of the joint
distribution of test statistics before adjusting the alpha level insures that correlation among
SNPs does not result in an overly conservative correction. The nominal alpha level for
genotype associations was 0.05, and the Monte Carlo-adjusted alpha level was 0.001. All
statistical tests were 2-sided.
To determine whether SNPs associated with breast cancer were associated with WHR, ORs
for the association between breast cancer-associated SNPs and WHR were estimated using
logistic regression in control subjects only, adjusting for BMI and the offset term.
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Haplotype analyses were performed using Hapstat [56, 57], which simultaneously estimates
the OR parameters and haplotype distribution for a given group of SNPs using maximum
likelihood estimation and the EM algorithm. This approach yields unbiased estimates of
ORs with appropriate variance estimates when haplotype phase is unknown. Modifications
to Hapstat allowed for inclusion of an offset term and relaxation of the assumption of
independence between genotypes and environmental variables [58].
For each gene, a 3-SNP sliding window was used to estimate a global P-value for the
association between case status and all possible haplotypes in the window. Estimation of
individual haplotype effects was pursued for haplotypes with a frequency ≥0.05 in controls
(online resource 3) that were present in windows with the strongest global associations (P <
0.01); an a priori cut-point was not used. Regions were also selected by reviewing genotype
ORs for consecutive strings of breast cancer-associated SNPs. Haplotype ORs and 95% CIs
were estimated using the codominant model, and adjusted for age, self-identified race,
ancestry, and the offset term. Haplotypes with a relatively strong OR (≥1.5 or ≤0.67) or a P
< 0.05 and a precise CI (CLR ≤ 5) are reported in the results. Haplotype analyses were
exploratory and predicated on SNP associations, and therefore were not adjusted for
multiple comparisons.
Multiplicative genotype- and haplotype-WHR interaction was tested by evaluating the
statistical significance of a multiplicative genotype- or haplotype-WHR interaction term.
Literature reviews have shown that associations between WHR and premenopausal breast
cancer were biased towards the null in studies that did not adjust for BMI [50, 51], and a
similar pattern was observed in the CBCS for the association between WHR and breast
cancer overall (data not shown). Therefore, BMI was included as a confounder in models
evaluating WHR interaction. Directed acyclic graph analysis suggested that menopausal
status, parity, and lactation were also potential confounders, but inclusion of these covariates
did not change the WHR-breast cancer subtype log ORs by ≥ 0.10, and they were not
included in final models. Genotype-WHR interaction was evaluated for all SNPs, and P-
values were adjusted for multiple comparisons using Monte Carlo methods, described
above. The nominal alpha level for interaction analyses was 0.10, and the Monte Carlo-




SNP associations with breast cancer overall were modest, with many effect estimates near
the null (Table 2). When stratified by subtype, some ORs were suggestive of specific
patterns: a group of 3 SNPs (rs17412175, rs9436746, and rs9436748) spanning 6786 base
pairs in LEPR intron 2 were inversely associated with basal-like breast cancer, with ORs
ranging from 0.48 to 0.57 (Table 2). The SNPs showed varying levels of moderate to low
LD in controls (online resource 4). Subtype-specific associations were less consistent for
ADIPOQ SNPs, some of which were inversely associated with the luminal A (rs16861194)
and basal-like (rs16861205) subtypes, and for LEP SNPs, some of which were positively
associated with luminal A (rs6976701, rs17151922) and basal-like (rs10954174) subtypes
(Table 2).
Candidate SNPs LEPR K109R (rs1137100) and Q223R (rs1137101) were positively
associated with luminal A breast cancer but not basal-like breast cancer, though associations
were not statistically different between the two subtypes (Table 2). In addition, K109R and
LEPR K656N (rs8179183) were associated with breast cancer overall (Table 2). ADIPOQ
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SNPs +45 T/G (rs2241766) and +276 G/T (rs1501299) were not associated with breast
cancer overall or by subtype (online resource 5).
Of the SNPs in Table 2, ADIPOQ rs16861194 and LEPR rs12042877 were associated with
WHR, though neither was in the direction expected based on the breast cancer risk allele
(online resource 6). No tag or candidate SNP associations with breast cancer were
statistically significant after accounting for multiple comparisons.
Haplotype associations
Haplotypes in LEP (haplotypes 1, 2a, 2b, 3) and LEPR (haplotype 6b) were strongly
associated with breast cancer overall or luminal A breast cancer, with ORs of 2 or greater
(Table 3). LEP haplotype 3 and LEPR haplotype 4a were associated with basal-like breast
cancer with moderate precision (Table 3); haplotype 4a includes rs17412175, rs9436746,
and rs9436748, which were each individually associated with basal-like breast cancer.
Overall, haplotype associations were stronger than individual SNP associations: the
strongest haplotype association was between haplotype 3 and luminal A breast cancer (OR =
3.21, Table 3), whereas the strongest SNP association was an OR of 0.48 (rs9436748 and
basal-like breast cancer, Table 2).
Interaction with WHR
Tests of multiplicative interaction between SNPs and WHR were not significant after
adjustment for multiple comparisons. In addition, there was no evidence of haplotype
interaction with WHR.
Discussion
We estimated associations between tag and candidate SNPs in ADIPOQ, LEP, and LEPR
and basal-like breast cancer, luminal A breast cancer, and breast cancer overall in a
population-based study of white and African American women. With respect to tag SNPs,
our main finding was that three LEPR SNPs (rs17412175, rs9436746, rs9436748) in close
proximity were inversely associated with basal-like breast cancer; associations between
these SNPs and luminal A breast cancer were weak. The SNPs are in moderate to weak LD
in cases and controls, and may be markers of a single genetic factor. Other SNP associations
showed few discernible patterns: SNPs in a particular gene were not associated only with the
basal-like subtype or only with the luminal A subtype. It is likely that many of these
associations represent false-positive results. As such, replication in an independent dataset is
necessary before further conclusions can be made.
Candidate SNPs in LEPR, but not ADIPOQ, were associated with luminal A breast cancer
and/or breast cancer overall (Table 2). LEPR Q223R (rs1137101) was positively associated
with luminal A breast cancer in the CBCS; however, the association was not as strong as
that reported by Snoussi et al. [27] (online resource 5). Q223R associations with breast
cancer have been inconsistent, and reported as both inverse [21, 28] and null [25, 29];
another study suggested that there was a positive association with breast cancer limited to
premenopausal women [30]. Quinton et al. [59] reported that the 223R variant was
associated with increased serum leptin levels, which is consistent with the hypothesis that
altered serum adipocytokine levels are part of the mechanism linking genetic variation to
breast cancer risk. Given that Q223R was associated only with luminal A breast cancer and
not breast cancer overall in our study, it is possible that some of the variation in results seen
in other studies is due to tumor heterogeneity and, more specifically, the relative proportion
of luminal A breast cancers in each population.
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LEPR K109R (rs1137100) was positively associated with breast cancer overall and the
luminal A subtype in the CBCS, in contrast to two previously reported null associations [28,
29]. Reports vary on the biological effect of LEPR K109R on serum leptin levels in women.
Two studies reported that healthy women with codon 109 RR variants had higher serum
leptin levels compared to women with 109 QR variants [28, 60]. In contrast, another study
reported that leptin levels were lower among postmenopausal women with at least one copy
of the 109R variant, and that there was no association among premenopausal women [61],
and two other studies reported no association [62, 63]. A limitation of our study was that
adipocytokine levels were not measured. Thus, although we observed associations between
Q223R, K109R, and K656N and breast cancer, we were unable to determine whether these
SNPs were also associated with changes in adipocytokine levels in our population. Analysis
of such intermediate markers can provide support for a hypothesized mechanism, and may
provide biological evidence to support genotype associations in future studies.
The molecular mechanisms by which K109R, K656N, or Q223R might affect the leptin
receptor have not been identified. A series of experiments showed that the Q223R
polymorphism did not affect transcription in mouse models or leptin receptor activity in
vitro [64], which conflicts with previously reported associations between Q223R and
circulating leptin levels [59, 65, 66]. Further research is necessary to confirm whether these
candidate SNPs have functional effects or are markers for other causal genetic variants.
Previously investigated candidate SNPs were not associated with basal-like breast cancer in
the CBCS. This may be due to greater imprecision for basal-like estimates because of the
smaller number of cases. Another potential explanation is that the candidate SNPs examined
in previous studies were examined in all breast cancer cases grouped together, the majority
of which are likely to be luminal A breast cancers. It is possible that different functional
variants are associated with basal-like tumors. Low penetrance variants specific to the basal-
like subtype are unlikely to be detected if basal-like cases constitute a minority of the overall
case group.
We used both agnostic (sliding window) and informed (based on SNP ORs) approaches to
identify haplotype effects, and found the two approaches to be complementary. Haplotype
associations were generally in the same direction as genotype associations for the involved
SNPs, and in many cases, the magnitude of the haplotype OR exceeded that of any single
SNP within the haplotype. Notably, in the case of LEP haplotype 1 the individual genotypes
showed no association with breast cancer overall or by subtype (online resource 7), but the
haplotype analysis revealed a strong association when the alleles were evaluated jointly.
Conversely, many of the breast cancer-associated haplotypes identified by evaluating SNPs
with strong genotype associations were not identified by the sliding window analysis. This is
likely because the sliding window analysis estimated a global test statistic for all possible
haplotypes within the SNP window. Such an analysis may have low power if the majority of
haplotypes are not associated with the outcome.
There was potential for selection bias to influence study results, since genotyping data were
more likely to be missing for cases and African Americans. Adjustment for self-identified
race and age should control for this possible selection bias, assuming that there was no
additional bias within case, race, and age strata [67]. Selection bias may have also occurred
when determining the breast cancer subtype, as sufficient immunohistochemistry was not
available for 47% of enrolled cases. However, genotype distributions between cases with
and without subtype information were similar, as was the molecular subtype distribution
comparing cases with and without genotyping data (data not shown). This suggests that the
genotype distribution in the subset of cases with tumor subtype information was likely
representative of the genotype distribution in all cases.
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Strengths of this study include analysis of a comprehensive set of tag SNPs enriched with
candidate SNPs to increase the chances of detecting a genomic region associated with breast
cancer. Tag SNPs were chosen from European and African populations to account for
different LD patterns among participants of African or European ancestry, and all
associations were adjusted for individual proportions of African ancestry, minimizing
residual con-founding due to population stratification within self-identified race groups.
Although estimates for the basal-like subtype were less precise compared to the luminal A
estimates due to smaller sample size, the results presented were chosen based on both OR
magnitude and precision to avoid reporting bias that would have resulted from using
statistical significance as the sole criteria for evaluating results by subtype.
In summary, the consistency of the strength and direction of association with basal-like
breast cancer points toward the 3-SNP region in LEPR intron 2 as a promising candidate for
an association with basal-like breast cancer risk. Furthermore, LEPR candidate SNPs K109R
and Q223R were associated with luminal A breast cancer and breast cancer overall. These
results suggest that genetic variation in LEPR may be associated with breast cancer risk, but
that specific regions may have subtype-specific effects.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Characteristics of CBCS participants with genotyping data
Controls All cases LuminalA Basal-like
N 1776 1972 679 200











 African American 658 742 233 108
 Non-African 1117 1229 446 92
 American
 Unknown 1 1
Menopausal status
 Premenopausal 761 879 277 111
 Postmenopausal 1015 1093 402 89
Waist-hip ratio
 <0.77 596 610 194 43
 0.77–0.83 478 549 204 60
 ≥0.84 681 784 274 92
 Missing 21 29 7 5
BMI (kg/m2)
 <25 545 712 243 57
 25 to <30 543 551 177 56
 30 to <35 338 349 132 39
 ≥35 313 319 112 43
 Missing 37 41 15 5
Stage
 CISa 838 151 18
 1 615 224 43
 2 635 237 108
 3 146 41 19
 4 43 8 6
 Missingb 1471 18 6
a
CIS carcinoma in situ
b
Invasive breast cancer cases
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